Pancreatic Adenosquamous Carcinoma clinical trials at UCSF
1 research study open to eligible people
Pancreatic adenosquamous carcinoma is a rare type of pancreatic cancer. UCSF is testing usual chemotherapy before and after surgery for this cancer. The aim is to compare it with chemotherapy given after surgery only.
Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer
open to eligible people ages 18 years and up
This phase III trial compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed by surgery (removable/resectable). Chemotherapy drugs, such as fluorouracil, irinotecan, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before and after surgery (perioperatively) may work better in treating patients with pancreatic cancer compared to giving chemotherapy after surgery (adjuvantly).
San Francisco, California and other locations
Our lead scientists for Pancreatic Adenosquamous Carcinoma research studies include Andrew H. Ko.
Last updated: